Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISIBLOOM vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ISIBLOOM is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby enhancing serotonin levels in the synaptic cleft.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder,Panic disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Prevention of pregnancy (FDA-approved)
Adults: 200 mg orally once daily; increase to 400 mg once daily after 2 weeks if tolerated. Maximum dose: 600 mg once daily.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults, permitting twice-daily dosing; prolonged to 24–30 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Hepatic metabolism primarily via CYP2D6 and CYP3A4 isoenzymes, producing active metabolites (e.g., nor ISIBLOOM).
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 35%; minor metabolism (<5%) via CYP3A4.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
92% bound to serum albumin and alpha-1-acid glycoprotein.
~99% bound to serum albumin and sex hormone-binding globulin.
0.8 L/kg (range 0.6–1.0 L/kg), indicating extensive extravascular distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 85% (range 75–95%) with high-fat meal increasing absorption by approximately 15%.
Oral: ~70% due to first-pass metabolism.
GFR ≥60 m L/min: no adjustment. GFR 30-59 m L/min: reduce dose to 200 mg daily. GFR 15-29 m L/min: 200 mg every 48 hours. GFR <15 m L/min or dialysis: not recommended.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (maximum 200 mg daily). Child-Pugh C: contraindicated.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Children ≥12 years: 200 mg orally once daily; increase to 400 mg once daily after 2 weeks. Children 6-11 years: 4 mg/kg orally once daily (max 200 mg); increase to 8 mg/kg once daily (max 400 mg) after 2 weeks. Children <6 years: not established.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Initiate at 200 mg once daily; monitor renal function and titrate slowly due to age-related decline in GFR. Maximum dose 400 mg daily.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
ISIBLOOM increases the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Patients of all ages should be closely monitored for clinical worsening, suicidality, or unusual changes in behavior.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Serotonin syndrome, discontinuation syndrome, activation of mania/hypomania, hyponatremia, abnormal bleeding, increased intraocular pressure, sexual dysfunction, and bone fractures.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Concomitant use with MAOIs, pimozide, thioridazine; known hypersensitivity to ISIBLOOM; use in patients with uncontrolled narrow-angle glaucoma.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Avoid grapefruit and grapefruit juice; inhibits CYP3A4 metabolism increasing drug levels. Take with or without food; if gastrointestinal upset occurs, take with food. Limit caffeine intake as it may exacerbate stimulant-like side effects.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Pregnancy Category X. First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and orofacial clefts based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Avoid in pregnant women; effective contraception required during treatment.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Contraindicated during breastfeeding. ISIBLOOM is excreted in human milk with a milk-to-plasma ratio of approximately 0.8. Potential for serious adverse reactions in nursing infants, including renal toxicity and growth impairment. Discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated in pregnancy; no dosing recommendation for use during pregnancy. Due to increased renal clearance and plasma volume expansion in pregnancy, if inadvertent exposure occurs, specific dose adjustments cannot be recommended. Drug should be discontinued immediately upon pregnancy detection.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Monitor for paradoxical worsening of mood symptoms during first 2 weeks; assess suicide risk. Reduce dose in hepatic impairment (Child-Pugh B/C). Avoid abrupt discontinuation to prevent withdrawal syndrome. QT interval prolongation risk; obtain baseline ECG in at-risk patients.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take exactly as prescribed; do not stop suddenly without doctor guidance.,May cause dizziness or drowsiness; avoid driving until effects known.,Report any new or worsening depression, anxiety, or suicidal thoughts immediately.,Avoid alcohol; may increase sedation and side effects.,Notify doctor if you have a history of heart rhythm problems (QT prolongation) or liver disease.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISIBLOOM vs AFIRMELLE, answered by our medical review team.
ISIBLOOM is a Oral Contraceptive that works by ISIBLOOM is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby enhancing serotonin levels in the synaptic cleft.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISIBLOOM and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISIBLOOM is: Adults: 200 mg orally once daily; increase to 400 mg once daily after 2 weeks if tolerated. Maximum dose: 600 mg once daily.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISIBLOOM and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISIBLOOM is classified as Category C. Pregnancy Category X. First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and orofacial clefts based on animal stu. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.